RxDoctor Payments DataLook up a doctor →

Madeleine Kitaj, MD

Neurology · Southbury, CTNPI 1881609451

Payments from drug & device makers

$186,537in general payments, 2019–2025

Across 1,305 payments — averaging $142.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$57K
  • Teva Pharmaceuticals USA, Inc.$52K
  • Amgen$34K
  • Lilly USA, LLC$15K
  • Biohaven Pharmaceuticals, Inc.$13K
  • Biohaven Pharmaceutical Holding Company Ltd.$7K
  • plus $9K from 27 others

What the payments were for

  • Consulting fees$2,2131%
  • Speaking & faculty fees$160,10886%
  • Grants$420%
  • Travel & lodging$3,9682%
  • Food & beverage$20,03511%
  • Education$1710%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$186,537 in reported general payments places this provider in the 85th percentile of 280 neurology providers in Connecticut.

See all neurology providers in Connecticut

Medicare billing

Part B allowed, 2024
$50,243
Medicare patients
105
Services billed
404

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Nurtec OdtRimegepant Sulfate77$167,634
UbrelvyUbrogepant75$101,339
QuliptaAtogepant55$87,311
Aimovig AutoinjectorErenumab-Aooe99$85,600
Emgality PenGalcanezumab-Gnlm50$53,765
Ajovy AutoinjectorFremanezumab-Vfrm17$19,055
Ajovy SyringeFremanezumab-Vfrm14$14,620
TrintellixVortioxetine Hydrobromide12$11,216
Sumatriptan Succinate119$6,594
Tizanidine Hcl174$4,790
Eletriptan HbrEletriptan Hydrobromide45$3,375
Cyclobenzaprine Hcl142$2,077
Pregabalin20$1,809
Divalproex Sodium ErDivalproex Sodium46$1,483
Sumatriptan11$1,482

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieUbrelvy, Qulipta$56,839$188,650130 claims
PfizerNurtec Odt$2,107$167,63477 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$1,178$11,21612 claims
Upsher-smith Laboratories LLCTopiramate$222$24024 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 280 neurology providers in Connecticut.

Other neurology in Southbury

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →